Literature DB >> 21949365

Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes.

Donna Wesolowski1, Hyun Seop Tae, Neeru Gandotra, Paula Llopis, Ning Shen, Sidney Altman.   

Abstract

Basic peptides covalently linked to nucleic acids, or chemically modified nucleic acids, enable the insertion of such a conjugate into bacteria grown in liquid medium and mammalian cells in tissue culture. A unique peptide, derived from human T cells, has been employed in a chemical synthesis to make a conjugate with a morpholino oligonucleotide. This new conjugate is at least 10- to 100-fold more effective than previous peptides used in altering the phenotype of host bacteria if the external guide sequence methodology is employed in these experiments. Bacteria with target genes expressing chloramphenicol resistance, penicillin resistance, or gyrase A function can effectively be reduced in their expression and the host cells killed. Several bacteria are susceptible to this treatment, which has a broad range of potency. The loss in viability of bacteria is not due only to complementarity with a target RNA and the action of RNase P, but also to a non-gene-specific tight binding of the complexed nontargeted RNA to the basic polypeptide-morpholino oligonucleotide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21949365      PMCID: PMC3189074          DOI: 10.1073/pnas.1112561108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Inactivation of gene expression using ribonuclease P and external guide sequences.

Authors:  C Guerrier-Takada; S Altman
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Cellular roles of DNA topoisomerases: a molecular perspective.

Authors:  James C Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2002-06       Impact factor: 94.444

Review 3.  Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.

Authors:  Jan Stenvang Jepsen; Mads D Sørensen; Jesper Wengel
Journal:  Oligonucleotides       Date:  2004

4.  Rapid selection of accessible and cleavable sites in RNA by Escherichia coli RNase P and random external guide sequences.

Authors:  Eirik W Lundblad; Gaoping Xiao; Jae-Hyeong Ko; Sidney Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-08       Impact factor: 11.205

5.  Phenotypic conversion of drug-resistant bacteria to drug sensitivity.

Authors:  C Guerrier-Takada; R Salavati; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  Gel retardation analysis of the interaction between C5 protein and M1 RNA in the formation of the ribonuclease P holoenzyme from Escherichia coli.

Authors:  S J Talbot; S Altman
Journal:  Biochemistry       Date:  1994-02-15       Impact factor: 3.162

7.  High-throughput, subpixel precision analysis of bacterial morphogenesis and intracellular spatio-temporal dynamics.

Authors:  Oleksii Sliusarenko; Jennifer Heinritz; Thierry Emonet; Christine Jacobs-Wagner
Journal:  Mol Microbiol       Date:  2011-03-17       Impact factor: 3.501

8.  The precursor tRNA 3'-CCA interaction with Escherichia coli RNase P RNA is essential for catalysis by RNase P in vivo.

Authors:  Barbara Wegscheid; Roland K Hartmann
Journal:  RNA       Date:  2006-10-24       Impact factor: 4.942

9.  Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.

Authors:  Saïd Abes; Hong M Moulton; Philippe Clair; Paul Prevot; Derek S Youngblood; Rebecca P Wu; Patrick L Iversen; Bernard Lebleu
Journal:  J Control Release       Date:  2006-09-30       Impact factor: 9.776

10.  Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.

Authors:  Lucas D Tilley; Brett L Mellbye; Susan E Puckett; Patrick L Iversen; Bruce L Geller
Journal:  J Antimicrob Chemother       Date:  2006-10-31       Impact factor: 5.790

View more
  21 in total

1.  Ribonuclease P.

Authors:  Sidney Altman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-27       Impact factor: 6.237

2.  Combined effect of a peptide-morpholino oligonucleotide conjugate and a cell-penetrating peptide as an antibiotic.

Authors:  Donna Wesolowski; Dulce Alonso; Sidney Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

3.  Gene selective mRNA cleavage inhibits the development of Plasmodium falciparum.

Authors:  Yoann Augagneur; Donna Wesolowski; Hyun Seop Tae; Sidney Altman; Choukri Ben Mamoun
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

Review 4.  Advances in therapeutic bacterial antisense biotechnology.

Authors:  John P Hegarty; David B Stewart
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

5.  Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis.

Authors:  Rekha G Panchal; Bruce L Geller; Brett Mellbye; Douglas Lane; Patrick L Iversen; Sina Bavari
Journal:  Nucleic Acid Ther       Date:  2012-09-14       Impact factor: 5.486

6.  Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum.

Authors:  Aprajita Garg; Donna Wesolowski; Dulce Alonso; Kirk W Deitsch; Choukri Ben Mamoun; Sidney Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

Review 7.  External guide sequence technology: a path to development of novel antimicrobial therapeutics.

Authors:  Carol Davies-Sala; Alfonso Soler-Bistué; Robert A Bonomo; Angeles Zorreguieta; Marcelo E Tolmasky
Journal:  Ann N Y Acad Sci       Date:  2015-04-09       Impact factor: 5.691

8.  A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model.

Authors:  Andrew J Sawyer; Donna Wesolowski; Neeru Gandotra; Alexander Stojadinovic; Mina Izadjoo; Sidney Altman; Themis R Kyriakides
Journal:  Int J Pharm       Date:  2013-05-29       Impact factor: 5.875

Review 9.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Authors:  Ryszard Kole; Adrian R Krainer; Sidney Altman
Journal:  Nat Rev Drug Discov       Date:  2012-01-20       Impact factor: 84.694

Review 10.  Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Matthew N Hurley; Miguel Cámara; Alan R Smyth
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.